The global market for cerebral malaria therapeutics is expected to grow at a tremendous rate over the coming years. A market research report by TMR highlights the key dynamics within the global market for cerebral malaria therapeutics. The title of the report is ‘Cerebral Malaria Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024’. The abysmal symptoms and ailments caused by cerebral malaria make it necessary to have effective therapeutics for the disease. Plasmodium falciparum, a unicellular protozoan parasite in humans, is the causative agent of cerebral malaria. The disease is characterized by neurological dysfunction in individuals, and in worst cases, cerebral malaria could lead to coma. The mortality rate relating to cerebral malaria is extremely high, and patients who survive often suffer from severe neurological impairments. Each year, there are around 500 million clinical cases of malaria, out of which 1% of the cases could lead to neurological malaria. The World Health Organization has explained cerebral malaria as a clinical syndrome causing coma, but the reasons for the coma remain largely unanalyzed. A relatively milder consequence of cerebral malaria as against coma is impaired consciousness. Other disorders including brain swelling, retinal changes, abnormalities in posture, and intracranial hypertension may also be observed in patients with cerebral malaria.
The global market is majorly driven by the development of novel drugs for the treatment of cerebral malaria. The extreme ailment caused by the disease prompts people to resort to every new treatment available in the market. Moreover, the availability of drugs over the counter has also enhanced the prospects of market growth in recent times. The cost of therapeutics for cerebral malaria have seen a decline due to the efforts of governments and healthcare centers to provide treatment facilities to all. This has also played a crucial role in escalating demand within the global market for cerebral malaria. Besides this, the acceptance rate of therapeutics has been rising which contributes to market growth. Despite the seemingly unobstructed growth of the market, addiction to therapeutic drugs and substance abuse has raised concerns with regards to the medications given for cerebral malaria. Furthermore, the lack of awareness across the rural areas of developing and underdeveloped countries could hinder the growth of the global market for cerebral malaria therapeutics.
Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20519
The medical industry of the United States has given commendable in the development of therapeutics for cerebral malaria. Owing to this factor, the market growth rate across North America supersedes the growth bar of all other regional markets. Europe stands second on the table of market share after North America while Asia Pacific is expected to catch up with the leading regional markets over the coming years.
Some of the key players in the market are Cipla, Inc., Sun Pharmaceutical Industries Ltd., Ipca Laboratories Ltd., and Guilin Pharmaceutical (Shanghai) Co.